News
FOR PAPULOPUSTULAR
ROSACEA1
PBS information: This product is not listed on the PBS.
Please review full Product Information before prescribing. Product Information is available on request from Galderma Medical Information: ph 1800 800 765.
SOOLANTRA ® Cream Ivermectin 10 mg / g. Indication: For the topical treatment of infl ammatory lesions of rosacea( papulo‐pustular) in adult patients 18 years and over. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Precautions: Contains excipients which may cause skin reactions, irritations or allergic reactions. Discontinue use if severe irritation or contact allergy occurs. Caution in patients suffering rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin or other facial dermatoses such as peri‐oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, acne and renal or hepatic impairment. Avoid excessive UV sun exposure. Refer to full PI. Use in pregnancy( Cat B3): use only if the potential benefi t to the mother justifi es the potential risk to the fetus. Paediatric Use: not recommended in children aged less than 18 years. Use in lactation: Excretion in human milk following topical application has not been evaluated. Risk to breast‐feeding child cannot be excluded. Interactions: Concomitant use with other topical or systemic medicinal products for treatment of rosacea has not been investigated. Adverse effects: Common adverse drug reactions( ≤1 %): skin burning sensation, skin irritation, pruritus and dry skin. Other common AEs( ≥1 %): nasopharyngitis, headache, upper respiratory tract infection, sinusitis, UTI, seasonal allergy, muscle strain, back pain. Post‐marketing experience: erythema. Dosage and administration: Apply once daily for up to 4 months, in fi ve pea‐sized amounts, totalling no more than 1g, as a thin layer to main areas of the face( i. e. forehead, chin, nose, cheeks). Treatment course may be repeated. Discontinue if no improvement after 3 months. Avoid application to eyes and lips. Apply a high SPF sunscreen to treated areas likely to be exposed to the sun, or other sun‐exposure reduction methods should be used( e. g. hats, clothing). Cosmetics may also be applied after SOOLANTRA has dried. Presentation: 60g, 45g, 30g, 15g and 2g tubes. Store below 30 ° C. S4. Based on approved PI dated: 9 November 2016.
REFERENCE: 1. SOOLANTRA Cream Approved Product Information( 9 November 2016).
®
Registered trademark of Galderma Australia Pty Ltd. ABN 12 003 976 930. 13B Narabang Way, Belrose, NSW 2085. SOO / 137 / 1115c. McCann Health 10699724. Date of preparation: FEBRUARY 2017.
SOOLANTRA. COM. AU
Mandatory reporting options unveiled
RACHEL WORSLEY HEALTH ministers have unveiled their vision to soften‘ mandatory reporting’ laws that make it compulsory for doctors to blow the whistle on impaired colleagues under their care.
A string of doctor suicides in recent years has cast a spotlight on the laws with many in the profession concerned that practitioners are failing to seek help for fear of being reported to AHPRA.
The COAG Health Council, which has already admitted that some reform is needed, has now released a discussion paper outlining four options.
Option 1. Keep things the way they are The current mandatory reporting regime applies across Australia, with the exception of WA. Treating practitioners have to report doctor-patients who are impaired, if they admit having been intoxicated while practising, have engaged in sexual misconduct or have departed from professional standards.
Based on the belief that past behaviour is a strong indicator of current and future behaviour, treating practitioners have to file reports where the practitioner has admitted placing the public at risk of substantial harm.
Option 2. The WA model Treating doctors would be exempt from reporting any health practitioner with a health issue that impairs their practice.
They would not be
GPs left in dark about patient needs
GEIR O’ ROURKE NEARLY a fifth of patients claim their GPs are not informed about their follow-up needs or medication changes after their most recent ED visit, national figures reveal.
The poor quality of clinical handover by hospitals looms large in the latest Australian Bureau of Statistics survey of healthcare co-ordination for those aged 45 and over.
Of the 36,000 people questioned, 9 % said their GPs had been kept in the dark by non-GP specialists about their care needs.
One-quarter of those surveyed who wanted to see a non-GP specialist privately said they had faced“ unacceptable” required to report admissions during a consultation about sexual misconduct and intoxication while practising.
Nor would they be required to report incidents where their patient admits to departing from professional standards.
This is the most radical option and has been in place in WA since 2010. It is supported by many doctor groups and medical defence organisations.
There would be no obligation for treating doctors to report their doctor-patients to AHPRA.
The discussion paper suggests it would also be the easiest option to implement nationwide.
Option 3. WA model, with mandatory reports, even for past behaviours Treating doctors would not have to report anyone who has a health issue that could impair their practice— unless they represent a
wait times, with half of them blaming the delays on having to save to afford the high appointment fees. substantial risk of harm to the public.
They would also be exempt if the major health issue happened in the past.
However, if the doctorpatient admits to sexual misconduct, departing from professional standards or being intoxicated while practising, the treating doctor would be required to report them to AHPRA. This includes both past and present cases.
Option 4. The WA model, except some mandatory reports will still apply
Treating doctors would be exempt from reporting anyone with a major health issue that impairs their practice.
However, they would still need to make reports if their patient admits to engaging in sexual misconduct or being intoxicated while practising or if the conduct poses a current or future risk to patients. Treating doctors would
Consumers Health Forum of Australia CEO Leanne Wells said she was troubled by the gaps in how information was
The information gaps are troubling, says Leanne Wells.
Many in the profession are concerned doctors aren’ t seeking help due to fears they will be reported to AHPRA.
also have to report those who have departed from professional standards, again if they pose a current or future risk to patient safety.
This option has been described as‘ therapeutic’ for doctor-patients because they can disclose past health issues without fear of being reported to AHPRA.
However, this option has been described as bad for the watchdog as it would hamper its ability to investigate complaints effectively.
Under this option, treating doctors would only report past cases of sexual misconduct, intoxication or departure from professional standards when deemed a current or future risk.
Submissions close on September 29. To read the COAG discussion paper in full go to bit. ly / 2xdo6NR. Submissions can be made by emailing legalmail @ doh. health. nsw. gov. au
disseminated to patients and GPs.
“ Significant numbers said their GPs did not seem informed about the care they received from specialists, or of their medication needs after their hospital visit.”
She said greater use of the My Health Record system should improve the situation.
Yet patient relationships with GPs appeared strong: 98 % of those surveyed who had seen a GP in the past 12 months said they had a regular GP or practice that they visited.
Two-thirds of those patients said their relationship with their GP had lasted for five years or more, suggesting that continuity of care was strong.
4 | Australian Doctor | 29 September 2017 www. australiandoctor. com. au